NCT03360682View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 13, 2018

Primary Completion Date

May 21, 2020

Study Completion Date

May 21, 2020

Conditions
HIV-1-infectionSolid Organ Transplant
Interventions
DRUG

Lamivudine 300 MG

Lamivudine 300 MG/day (48 weeks)

DRUG

Abacavir 600 MG

Abacavir 600 MG/day (48 weeks)

DRUG

Dolutegravir 50 mg

Dolutegravir 50 MG/day (48 weeks)

DRUG

Tenofovir Disoproxil 245Mg Tablet

Tenofovir 245 MG/day (48 weeks)

DRUG

Emtricitabine 200 MG

Emtricitabine 200 MG/day (48 weeks)

Trial Locations (1)

08036

Hospital Clínic de Barcelona, Barcelona

All Listed Sponsors
lead

Fundacion Clinic per a la Recerca Biomédica

OTHER

NCT03360682 - Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients | Biotech Hunter | Biotech Hunter